SCHEMBL24476668

SCHEMBL24476668

C#C[C@]1(O)CC[C@@H]2[C@@H]3CCC4=CC(=O)C=C[C@@H]4[C@@H]3CC[C@@]21C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 7/20 0.66
▸ LMNA P02545 6/20 0.66
▸ PGR P06401 5/20 0.66
▸ ESR1 P03372 5/20 0.66
▸ SHBG P04278 5/20 0.66
▸ CYP2C19 P33261 4/20 0.66
▸ ABCB11 O95342 4/20 0.66
▸ NR3C1 P04150 4/20 0.66
▸ SLC6A4 P31645 4/20 0.66
▸ HIF1A Q16665 3/20 0.66
▸ TSHR P16473 3/20 0.66
▸ ALDH1A1 P00352 2/20 0.66
▸ ADRA2A P08913 1/20 0.66
▸ CYP1A2 P05177 2/20 0.58
▸ CYP2C9 P11712 2/20 0.58
▸ OPRK1 P41145 2/20 0.58
▸ MAOA P21397 1/20 0.58
▸ PDK1 Q15118 1/20 0.58
▸ PDK2 Q15119 1/20 0.58
▸ PDK3 Q15120 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24476407 0.84 PGR (0.53) CYP3A4LMNAPGRESR1SHBG
Norethindrone SCHEMBL14577661 0.80 CYP3A4 (1.00) CYP3A4LMNAPGRESR1SHBG
Norethindrone SCHEMBL7768886 0.80 CYP3A4 (1.00) CYP3A4LMNAPGRESR1SHBG
Norethindrone SCHEMBL11781372 0.80 CYP3A4 (1.00) CYP3A4LMNAPGRESR1SHBG
Norethindrone SCHEMBL14074493 0.80 CYP3A4 (1.00) CYP3A4LMNAPGRESR1SHBG
Norethindrone SCHEMBL19510084 0.80 CYP3A4 (1.00) CYP3A4LMNAPGRESR1SHBG
Norethindrone SCHEMBL6834811 0.80 CYP3A4 (1.00) CYP3A4LMNAPGRESR1SHBG
Norethindrone SCHEMBL24476231 0.80 CYP3A4 (1.00) CYP3A4LMNAPGRESR1SHBG
Norethindrone SCHEMBL23390 0.80 CYP3A4 (1.00) CYP3A4LMNAPGRESR1SHBG
Norethindrone SCHEMBL5021649 0.80 CYP3A4 (1.00) CYP3A4LMNAPGRESR1SHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169672-A1 COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER PURDUE RESEARCH FOUNDATION 2022-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169672-A1 COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER KLK3, AR, ACP3 CYP3A4 3616/4885LMNA 4233/4885PGR 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback